Petra Danielsohn-Weil Ph.D. serves as Independent Director of the Company. From 2014 until her retirement in August 2017, Ms. Danielsohn-Weil was the Regional President for Pfizer Essential Health - Europe. Pfizer Essential Health is a producer of non-viral anti-infectives, biosimilars and sterile injectable medicines and is a business unit of Pfizer Inc. (NYSE:PFE), a research-based, global biopharmaceutical company. Ms. Danielsohn-Weil previously served in various general management, regional and global business unit executive roles in Europe and the United States for Pfizer from 2000 through 2014. Prior to that she served in various commercial and strategic leadership roles in Europe and the US for Warner-Lambert from 1988 until its acquisition by Pfizer in 2000. She serves as a board member of NovaMedica LLP, a pharmaceutical company owned by Russian and U.S. investors and a portfolio company of Rusnano JSC Corporation. Since 2019, Ms. Danielsohn-Weil has been a member of the supervisory Board of Gruenenthal Pharma.
As the Independent Director of Invacare, the total compensation of Petra Weil at Invacare is $240,270. There are 13 executives at Invacare getting paid more, with Matthew Monaghan having the highest compensation of $8,340,920.
Petra Weil is 60, she's been the Independent Director of Invacare since 2018. There are 4 older and 14 younger executives at Invacare. The oldest executive at Invacare Corp. is Susan Alexander, 63, who is the Independent Director.
Petra's mailing address filed with the SEC is ONE INVACARE WAY, , ELYRIA, OH, 44035.
Over the last 21 years, insiders at Invacare have traded over $3,551,958 worth of Invacare stock and bought 391,450 units worth $2,325,949 . The most active insiders traders include Edward F Crawford, Aaron Malachi Iii Mixon, and Steven H Azurite Management.... On average, Invacare executives and independent directors trade stock every 52 days with the average trade being worth of $10,700. The most recent stock trade was executed by Steven H Azurite Management... on 17 November 2022, trading 122,820 units of IVC stock currently worth $47,900.
Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the Company designs, manufactures, and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The Company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The Company's products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. The Company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, distributors and government health services in North America, Europe and Asia Pacific.
Invacare executives and other stock owners filed with the SEC include: